Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca

(European Society for Medical Oncology) The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.
Source: EurekAlert! - Biology - Category: Biology Source Type: news